Linked Data API

Show Search Form

Search Results

1125504
star this property registered interest false remove filter
star this property date less than 2019-05-08more like thismore than 2019-05-08
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Pneumococcal Diseases: Vaccination more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of the recommendations by the Joint Committee on Vaccination and Immunisation to reduce the infant pneumococcal vaccination schedule from three doses to two. more like this
star this property tabling member printed
Baroness Masham of Ilton more like this
star this property uin HL15599 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-05-22more like thismore than 2019-05-22
unstar this property answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom’s immunisation programme. As an independent committee, it is well placed to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme. It bases its advice on review of a wide range of scientific and other evidence, including from the published literature, commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness.</p><p>The JCVI advised that a two-dose schedule for the infant pneumococcal conjugate vaccine (PCV) Prevenar13 is appropriate for the UK. Its advice takes into account the public health aspects of any potential change to the vaccination schedule, such as the potential impact on cases of infectious disease. The JCVI consulted relevant stakeholders on its proposed advice, between January and April 2018, to ensure that its advice reflects all the evidence.</p><p>The JCVI’s advice on the infant pneumococcal programme was given full consideration, including the potential public health implications, before a decision was made to implement it. The UK frequently adopts innovative immunisation schedules and we regularly change the vaccine schedule following the advice of our independent expert committee, as we are doing in this case.</p><p>The decision is based on the excellent effectiveness of the vaccine and years of high uptake, which has helped to provide protection to the rest of the population and has successfully controlled many types of pneumococcal disease in this country. The evidence shows that two doses will sustain the excellent results we have already seen. We are confident that the world-class disease surveillance system we have in this country means our expert committee can closely monitor the impact of this change. This is set out in the JCVI’s minutes which are attached.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL15600 more like this
star this property question first answered
less than 2019-05-22T14:50:14.54Zmore like thismore than 2019-05-22T14:50:14.54Z
unstar this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford remove filter
star this property attachment
1
star this property file name JCVI Minute 2015 10 Attached to HL16000 and 15999.pdf more like this
star this property title JCVI Minute 2015 more like this
star this property tabling member
1850
unstar this property label Biography information for Baroness Masham of Ilton more like this
1125505
star this property registered interest false remove filter
star this property date less than 2019-05-08more like thismore than 2019-05-08
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Pneumococcal Diseases: Vaccination more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what analyses they have conducted of the risks and benefits of reducing the infant pneumococcal vaccination schedule from 2+1 to 1+1; and whether they will publish the results any such analyses. more like this
star this property tabling member printed
Baroness Masham of Ilton more like this
star this property uin HL15600 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-05-22more like thismore than 2019-05-22
unstar this property answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom’s immunisation programme. As an independent committee, it is well placed to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme. It bases its advice on review of a wide range of scientific and other evidence, including from the published literature, commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness.</p><p>The JCVI advised that a two-dose schedule for the infant pneumococcal conjugate vaccine (PCV) Prevenar13 is appropriate for the UK. Its advice takes into account the public health aspects of any potential change to the vaccination schedule, such as the potential impact on cases of infectious disease. The JCVI consulted relevant stakeholders on its proposed advice, between January and April 2018, to ensure that its advice reflects all the evidence.</p><p>The JCVI’s advice on the infant pneumococcal programme was given full consideration, including the potential public health implications, before a decision was made to implement it. The UK frequently adopts innovative immunisation schedules and we regularly change the vaccine schedule following the advice of our independent expert committee, as we are doing in this case.</p><p>The decision is based on the excellent effectiveness of the vaccine and years of high uptake, which has helped to provide protection to the rest of the population and has successfully controlled many types of pneumococcal disease in this country. The evidence shows that two doses will sustain the excellent results we have already seen. We are confident that the world-class disease surveillance system we have in this country means our expert committee can closely monitor the impact of this change. This is set out in the JCVI’s minutes which are attached.</p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL15599 more like this
star this property question first answered
less than 2019-05-22T14:50:14.483Zmore like thismore than 2019-05-22T14:50:14.483Z
unstar this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford remove filter
star this property attachment
1
star this property file name JCVI Minute 2015 10 Attached to HL16000 and 15999.pdf more like this
star this property title JCVI Minute 2015 more like this
star this property tabling member
1850
unstar this property label Biography information for Baroness Masham of Ilton more like this
1125506
star this property registered interest false remove filter
star this property date less than 2019-05-08more like thismore than 2019-05-08
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading HIV Infection: Vaccination more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what steps they are taking to improve vaccination coverage for people living with HIV. more like this
star this property tabling member printed
Baroness Masham of Ilton more like this
star this property uin HL15601 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-05-22more like thismore than 2019-05-22
unstar this property answer text <p>Public Health England, in partnership with NHS England and the Department, is taking steps to improve vaccination coverage in England, including for people living with HIV.</p><p>These steps include initiatives to improve access to the immunisation programme; communication with the public; data to identify underserved individuals and populations; and training for healthcare professionals, changes to vaccination eligibility criteria; launching disease elimination strategies; running targeted social media campaigns; providing information leaflets in multiple languages and running e-learning programme for healthcare practitioners.</p><p>Certain vaccines are delivered through sexual health services that particularly benefit people living with HIV. This includes vaccines for hepatitis A, hepatitis B and human papillomavirus. People living with HIV are in the influenza risk groups and are invited for the flu vaccine on an annual basis.</p> more like this
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
less than 2019-05-22T14:50:46.107Zmore like thismore than 2019-05-22T14:50:46.107Z
unstar this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford remove filter
star this property tabling member
1850
unstar this property label Biography information for Baroness Masham of Ilton more like this
1126321
star this property registered interest false remove filter
star this property date less than 2019-05-13more like thismore than 2019-05-13
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Gender Dysphoria: Children more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government whether they intend to publish the results of the research project started in 2011 by the NHS Gender Identity Development Service Early pubertal suppression in a carefully selected group of adolescents with gender identity disorder; and if not, whether they will arrange for the data gathered by that study to be made available to other researchers. more like this
star this property tabling member printed
Lord Lucas more like this
star this property uin HL15681 more like this
star this property answer
answer
star this property is ministerial correction true more like this
star this property date of answer less than 2019-05-22more like thismore than 2019-05-22
unstar this property answer text <p>The research is an ethically approved study being carried out by the Tavistock and Portman NHS Foundation Trust since 2011, which is the largest provider of services for the alleviation of gender dysphoria in the United Kingdom.</p><p>The study will evaluate early pubertal suppression in a carefully selected group of adolescents with a clinical diagnosis of gender dysphoria. There are 44 young people taking part in the study.</p><p>The Tavistock and Portman NHS Foundation Trust has plans to publish the data <ins class="ministerial">on the blocker and cross-sex hormones, for those who were appropriate for this, as</ins><del class="ministerial">once</del> all of the young people in the study have reached <ins class="ministerial">this</ins><del class="ministerial">the</del> stage<ins class="ministerial">.</ins> <del class="ministerial">when a clinical decision is made about moving from pubertal suppressants to cross-sex hormones, which the Trust expects to occur in the next 12 months.</del></p>
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property question first answered
remove maximum value filtermore like thismore than 2019-05-22T14:51:30.447Z
star this property question first ministerially corrected
less than 2019-07-31T15:30:59.74Zmore like thismore than 2019-07-31T15:30:59.74Z
unstar this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford remove filter
star this property previous answer version
119577
star this property answering member printed Baroness Blackwood of North Oxford more like this
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
1879
unstar this property label Biography information for Lord Lucas more like this